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Abstract: Mantle cell lymphoma (MCL) is a rare and aggressive subtype of lymphoma 
associated with a poor prognosis. Chemotherapy is the mainstay of frontline treatment for 
patients with this disease. Despite high response rates to combination chemotherapy regimens, 
the majority of patients relapse within a few years of treatment. Therefore, finding efficacious 
treatments for relapsed or refractory disease has become a growing area of clinical research. 
The mammalian target of rapamycin (mTOR) is responsible for integrating cell signals from 
growth factors, hormones, and nutrients and communicating energy status. Scientific research 
on aberrant molecular pathways in cancer has revealed that several proteins along the mTOR 
pathway may be upregulated in this and other types of lymphoma. Temsirolimus is the first 
mTOR inhibitor that has shown clinical efficacy in treating MCL that has relapsed after 
frontline treatments.
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Current practices in managing mantle  
cell lymphoma
introduction
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma 
(NHL). Despite having been identified as a clinically and morphologically unique 
type of lymphoma 20 years ago, MCL lacks a standard-of-care   regimen in   current 
treatment approaches. Although efficacious frontline treatments with   combination 
chemotherapy regimens have been identified, the rate of relapse remains unacceptably 
high. A growing body of research suggests targeted therapies hold promise for patients 
with relapsed or refractory disease. Among these new targeted agents is a class of 
drugs called mammalian target of rapamycin (mTOR) inhibitors. Temsirolimus, the 
first drug in this class marketed as an anticancer agent, has shown in vitro and in vivo 
activity against MCL. This review of the literature will discuss the application and use 
of temsirolimus in relapsed or refractory MCL.
NHL is the most commonly seen hematologic malignancy in the United States. 
According to the American Cancer Society, it is the fourth leading cause of cancer in 
women and the fifth leading cause of cancer in men in the United States; an estimated 
65,980 people were diagnosed with the disease in 2009. NHL encompasses a large 
and heterogeneous group of lymphomas, each with unique pathologic and clinical 
characteristics. Among the more than 30 subtypes of NHL, MCL accounts for 6% of 
cases and carries the worst prognosis.1OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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MCL is an aggressive lymphoma with a short overall 
  survival (OS) duration when left untreated; the median OS 
duration is 3–5 years.2–6 The majority of patients have pro-
gressed to advanced stages (III or IV) of the disease by the 
time of diagnosis and often have disease outside of the lymph 
nodes.3 The most frequent sites of extranodal involvement 
are the bone marrow, peripheral blood, and gastrointestinal 
tract.4 The disease has a slight male predominance, and 
patients are typically in their seventh decade of life at the 
time of diagnosis.5
Specific clinical features have been identified as prognostic 
factors and are used to calculate a prognostic score called the 
Mantle cell International Prognostic Index (MIPI).7 Indicators 
of poor prognosis (low performance status, advanced age, high 
lactate dehydrogenase levels, and leukocytosis) are assigned 
values and added together. The corresponding score may be 
useful for predicting the clinical course of an individual’s 
disease and has the potential to help guide treatment.
Newly diagnosed MCL
In a very small subset of patients, MCL has an indolent 
course. A watch-and-wait method has been used in these 
patients and may be reasonable as long as their disease 
progression remains slow.8 For the majority of patients with 
MCL, however, the prompt initiation of cytotoxic therapy is 
warranted. Chemotherapy is the mainstay of frontline treat-
ment, and the addition of biologic therapy (eg, rituximab) 
has become a widely accepted standard. Consolidation treat-
ment using high-dose chemotherapy followed by autologous 
hematopoietic stem cell transplantation is now a growing 
area of clinical research in this setting.
Current options for frontline therapy include   combination 
regimens, usually involving multiple conventional chemo-
therapy agents, rituximab, and corticosteroids. Early data 
with rituximab, cyclophosphamide, doxorubicin, vincristine, 
and prednisone (R-CHOP) therapy demonstrated favorable 
initial responses in patients with MCL, but not the increase 
in survival that was demonstrated in other subtypes of 
NHL using the same regimen.9 A prospective single-center 
study assessed the efficacy of a more dose-intense regimen 
  involving rituximab, cyclophosphamide, vincristine, doxoru-
bicin, and dexamethasone alternating with methotrexate and 
cytarabine (R-hyperCVAD/MA).10 The authors of the latter 
trial concluded that dose intensification does increase 
response rates and has the potential to increase OS.11 More 
recently, a prospective multicenter study by the Southwest 
Oncology Group attempted to replicate these results and 
confirmed the high response rates seen in the single-center 
study.12 A newer approach in the frontline setting involves 
studying the   combination of R-hyperCVAD/MA with 
targeted therapies like bortezomib, a proteosome inhibitor 
approved for relapsed MCL, with the hopes of increasing 
first-line efficacy. Studies of this combination are currently 
underway.
One limitation of the R-hyperCVAD/MA regimen is the 
high rate of adverse events associated with the MA cycles, 
especially in patients older than 60 years.10 In an attempt 
to decrease toxicity while maintaining efficacy with this 
  regimen, the Wisconsin Oncology Network performed a small 
Phase II study to assess the use of a modified R-  hyperCVAD 
regimen – one that did not have alternating MA cycles and 
instead included a maintenance program using rituximab.13 
This study demonstrated that modified R-hyperCVAD 
produced overall response rates (ORRs) comparable to the 
original regimen and had a lower incidence of adverse events 
despite the study’s inclusion of an older patient population. 
Recently, a retrospective study observing patients with MCL 
treated at a single center over time concluded that less dose-
intense therapy (eg, R-CHOP) may yield similar rates of OS 
as R-hyperCVAD/MA, despite higher rates of initial response 
to dose-intense therapy.14
The role of high-dose chemotherapy followed by 
autologous hematopoietic stem cell transplantation has 
also been studied in MCL. Initially, it was reserved for 
treatment of patients with relapsed disease after response to 
second-line chemotherapy. However, preliminary evidence 
failed to show long-term remissions using this strategy.15 
Not surprisingly, given that prognosis worsens with each 
failed therapy, the subset of patients who had been through 
fewer lines of therapy seemed to benefit more than those 
who had received multiple lines of treatment prior to 
transplantation.16 In line with this decrease in efficacy with 
subsequent treatments, earlier autologous hematopoietic 
stem cell transplantations following response to frontline 
therapy have produced positive results in several prospec-
tive studies.17,18 Of note, patients whose disease achieves 
complete or partial   remission after induction chemotherapy 
had better rates of OS and   progression-free survival (PFS) 
after autologous hematopoietic stem cell   transplantation.19 
One recent study implemented an intensified induction 
chemotherapy regimen followed by autologous hematopoi-
etic stem cell transplantation in newly diagnosed patients 
with MCL and found a high rate of PFS at 2 years, provid-
ing further encouraging evidence for the use of upfront OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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transplantations in MCL.20 New data on allogeneic and 
nonmyeloablative stem cell transplantations are adding to 
the already expanding choices of transplant schemas in 
MCL; however, their discussion is beyond the scope of 
this review.
Relapsed or refractory MCL
Despite favorable responses to chemotherapy in de novo 
MCL, most patients will experience a recurrence of their 
disease. Treating patients with relapsed or refractory dis-
ease presents a challenge because response rates are lower 
in this setting than they are in frontline treatments. Treat-
ment options in the second-line setting have historically 
been limited, with the use of multiagent chemotherapy 
regimens showing only marginal utility. However, with the 
advent of newer agents and targeted therapies, the options 
are expanding. Bortezomib, the first in its class of protea-
some inhibitors, was the first agent to be approved by the 
United States Food and Drug Administration (FDA) for use 
in relapsed or refractory MCL.21–24 Bendamustine, a new 
agent encompassing properties of both purine analogs and 
alkylating agents, has been used in this setting as part of 
combination therapy and has shown promising results.25–28 
More data are emerging on the use of thalidomide and 
lenalidomide, two multifunctional immunomodulatory 
agents, as second-line treatments.29,30 Another promising 
new agent in this setting is temsirolimus, an analog of the 
immunosuppressant drug sirolimus (first known as rapamy-
cin), which has shown efficacy in treating relapsed or 
refractory MCL. Table 1 compares the efficacy and general 
toxicities of the second-line agents currently employed in 
treating MCL as observed in Phase II trials.
Targeting the PI3K/Akt/mTOR 
survival pathway
Rapamycin was isolated from the bacteria Streptomyces 
hygroscopicus and has been approved by the FDA as 
an immunosuppressive agent. Since the discovery of 
  rapamycin in the 1970s, the study of its effects on cells 
has helped scientists explore new intracellular signaling 
mechanisms, namely those involving the plasma mem-
brane protein phosphatidylinositol 3-kinase (PI3K). The 
activation of PI3K causes changes within the cell through 
the phosphorylation of a variety of downstream effector 
proteins. One of these proteins is Akt, a serine/threonine 
kinase, which has more than 50 potential downstream 
targets and is directly activated by PI3K.33 One of the 
most critical proteins affected by Akt is mTOR. Taken 
together, the PI3K/Akt/mTOR pathway helps control cell 
metabolism, survival, and proliferation through the activa-
tion and inactivation of various proteins, as demonstrated 
in Figure 1.
Early clinical trials with rapamycin noted the drug’s 
cytostatic properties and its potential as an antitumor agent.34 
Scientists found that rapamycin exerts its effect on the cell 
by binding to the 12-kDa immunophilin FK506-binding 
protein (FKBP12) and that the FKBP12–rapamycin complex 
inhibits the activity of mTOR.35 This prompted an area of 
research using mTOR inhibitors for anticancer therapy and 
increased interest in targeting various aspects of the PI3K/
Akt/mTOR pathway.
Current evidence suggests that mTOR exists as a multi-
protein complex, with its downstream effects being regulated 
by its association with various proteins, growth factors, and 
nutrients. Researchers have isolated two specific complexes, 
Table 1 The comparative efficacy of second-line agents in MCL (data from select Phase II trials)
Clinical trials in relapsed  
or refractory MCL
N PR CR ORRa Significant AEb
Bortezomib21 141 26% (36/141) 6% (9/141) 47%  Fatigue, thrombocytopenia, neuropathy
Bortezomib22 28 43% (12/28) 0 46.4%
Bortezomib23 29 21% (6/29) 21% (6/29) 41% (12/29)
Bortezomib24 10 40% (4/10) 0 50% (5/10)
Lenalidomide30  15 33% (5/15) 20% (3/15) 53% (8/15) Neutropenia, leucopenia, thrombocytopenia
Thalidomide29 16 50% (8/16) 25% (4/16) 81% (13/16) Somnolence, neuropathy, constipation
Bendamustine + fludarabine25 9 66% (6/9) 33% (3/9) 100% (9/9) Leukopenia, neutropenic fever,  
thrombocytopenia, anemia Bendamustine + rituximab26 16 25% (4/16) 50% (8/16) 75% (12/16)
Bendamustine + rituximab +  
mitoxantrone28
18 44% (8/18) 33% (6/18) 78% (14/18)
Temsirolimus31 27 37% (10/27) 4% (1/27) 41% (11/27) Thrombocytopenia, fatigue,  
hyperglycemia, dyspnea Temsirolimus32 34 35% (12/34) 3% (1/34) 38% (13/34)
Notes: aORR based on PR and CR. bGenerally grade 3 or higher.
Abbreviations: N, number of patients with MCL evaluable for efficacy; PR, partial response; CR, complete response; ORR, overall response rate; AE, adverse events.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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mTORC1 and mTORC2, each leading a separate branch of 
the mTOR pathway. The mTORC1 complex includes mTOR 
and a protein called regulatory-associated protein of mTOR, 
whereas mTORC2 is made of mTOR and the rapamycin-
insensitive companion of mTOR protein.36 Essentially, 
activated mTOR is responsible for integrating cellular signals 
and triggering downstream targets.
Among other functions, mTORC1 is responsible for the 
phosphorylation of two substrates – ribosomal p70 S6 kinase 
(S6K1) and elongation initiation factor 4E (eIF4E)-binding 
protein 1 (4E-BP1).37 Activated S6K1 promotes protein 
synthesis by allowing translation of ribosomal proteins. 
The phosphorylation of 4E-BP1 causes disassociation from 
eIF4E, thus allowing eIF4E to recruit ribosomes to mRNA 
via association with the mRNA cap. The result of mTOR-
activated translation of mRNA is the production of proteins 
that are necessary for G1 cell-cycle progression and initiation 
of the S phase.38 Passage from G1 to S phase is considered 
the most crucial step in the cell cycle.
Although the exact mechanism by which mTOR regulates 
cell-cycle progression is not well understood, one proposed 
mechanism includes the eIF4E-dependent nuclear   transport 
and translation of mRNAs that encode for cell-cycle 
  regulators such as cyclin D1.39,40 In general, the cyclins are 
a group of proteins that guide cell cycling from one phase 
to another. Four different classes of cyclins exist (A, B, D, 
and E), and each is responsible for regulating different phases 
of the cell cycle. The role of cyclin D includes promoting 
the gene transcription involved in the transition from G1 to 
S phase.
Rationale for targeting mTOR  
for cancer therapy
A close study of mTOR’s central role in intracellular   signaling 
and advances in research on deregulated signaling pathways 
in cancer have led scientists to study the effects of aberrant 
mTOR function. Through years of research, scientists have 
found correlative data to suggest that mTOR deregulation can 
lead to tumorigenesis via increased cell growth and survival 
and via decreased apoptosis.
Deregulation of proteins upstream of mTOR
In normal cells, mTORC1 activation represses PI3K–Akt 
signaling upstream via a negative feedback mechanism 
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involving S6K1.41 In addition, the tumor suppressor gene 
PTEN can inhibit Akt activation via a reduction in levels 
of P13K in the cell membrane.42 In support of this finding, 
cells that lack PTEN exhibit a constitutively active form of 
Akt.43 Loss of PTEN from gene alteration or deletion has been 
found in a variety of human cancers, including lymphoid 
neoplasms.44,45 Other mechanisms of increased PI3K–Akt 
activity include the amplification of genes that encode for 
Akt.46 An alternate hypothesis suggests that mTORC2 can 
directly activate Akt, thus circumventing the negative feed-
back mechanism led by S6K1.47
Deregulation of proteins downstream of mTOR
The overexpression of the downstream protein eIF4E in 
cancer cells coincides with an increase in tumorigenesis 
and has become an increasingly vigorous area in oncology 
research. Scientists have shown that cells exhibiting an 
overexpression of eIF4E have markedly increased levels of 
cyclin D1.48 One explanation for this finding is an increase 
in eIF4E-facilitated transport of cyclin D1 mRNA from the 
cell nucleus to the cytoplasm.49 The clinical importance of 
eIF4E function is supported by evidence in human cancer 
cells. A strong expression of eIF4E has been observed in 
some NHL cell lines, particularly in the aggressive and highly 
aggressive subtypes, suggesting that the level of eIF4E may 
be predictive of the clinical characteristics and behavior of 
particular cancers.50
Studies on mouse xenografts have demonstrated that 
in addition to its effects on cell-cycle progression, eIF4E 
participates in the activation of a pathway that suppresses 
apoptosis.51 In normal cells, mTOR suppresses the DNA 
repair protein p53 during periods of cell proliferation. This 
occurs via the protein MDM2, from the murine double minute 
(MDM) oncogene, which is a negative regulator of p53. The 
normal function of p53 is to enable DNA repair and trigger 
apoptosis in cells that cannot be repaired after DNA damage. 
Elevated levels of eIF4E in oncogenic cells – possibly via the 
upregulation of mTOR – can lead to an upsurge in transport 
of MDM2 mRNA from the nucleus.52 The enhanced levels 
of MDM2 can boost p53 inhibition and upset the balance 
between cell proliferation and programmed cell death, thus 
leading to tumor growth.52
Another group of proteins downstream of mTOR 
involved in cell growth and proliferation includes those 
encoded by the Myc family genes: c-Myc, N-Myc, and L-Myc. 
Studies on murine models have demonstrated that c-Myc 
enhances protein synthesis during lymphocyte development 
and carries the ability to induce apoptosis in quiescent 
cells.53 The overexpression of c-Myc has been implicated in 
the   pathogenesis of B-cell lymphomas, especially in more 
aggressive subtypes. Research has indicated that lymphom-
agenesis involving c-Myc may be accelerated by various 
cell-cycle proteins such as cyclin D1.54 In addition, elevated 
levels of eIF4E may further augment the effects of cyclin 
D1 on cells with deregulated c-Myc.55 Studies show that 
overexpression of eIF4E inhibits c-Myc-induced apoptosis.51 
Since c-Myc is also an upstream activator of eIF4E, c-Myc 
may induce a feedback mechanism for suppression of its own 
proapoptotic function via increased eIF4E.56
Hypoxia-inducible factor (HIF) is a family of transcrip-
tion factors involved in angiogenesis, glucose metabolism, 
and apoptosis regulation, which are activated under hypoxic 
conditions in the cell.57 Researchers have reported an increase 
in HIF1α in hematologic malignancies despite conditions of 
normoxia.58 This increase may be due to the effects of Akt-
mediated translation of HIF.59 Interestingly, the upregula-
tion of HIF1α was found to correlate with the presence of 
aberrant mTORC1 pathways.60 It is possible that tumor cells 
overexpressing Akt may increase HIF1α expression via the 
upregulation of mTOR.
Rationale for using mTOR inhibitors  
for the treatment of MCL
MCL can be differentiated from other subtypes of NHL 
by the expression of the translocation t(11;14)(q13;q32) 
observed by fluorescence in situ hybridization (FISH) and 
the subsequent overexpression of the cyclin D1 protein as 
seen by immunohistochemical (IHC) analysis. The t(11;14) 
determines the deregulated expression of cyclin D1 in 
lymphoid cells because of its proximity to B-cell immuno-
globulin heavy chain transcription enhancers.38 Two other 
types of cyclin D proteins, D2 and D3, also exist, and each 
is specific to certain tissues. Cyclins D2 and D3 are used in 
normal lymphoid cells, but are replaced by overexpressed 
cyclin D1 in cases of MCL.61
Various additional proteins have also been shown to be 
upregulated in MCL. As mentioned earlier, PI3K/Akt is a 
major signaling pathway that regulates cell growth and cell 
death through a variety of molecular pathways, including 
mTOR activation. Interestingly, the PI3K/Akt pathway 
has been found to be constitutively active in some cases of 
MCL. In one study, the upregulation of Akt increased the 
antagonistic activity of phosphorylated MDM2 against p53, 
which is analogous to earlier preclinical data.62 A strong 
correlation between upregulation of Akt and the presence 
of activated mTOR was also observed, although mTOR OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  activation through Akt-independent pathways could not 
be ruled out. In further support of these data, another study 
showed the increased activation of the mTOR pathway in 
MCL cell lines and found enhanced Akt activation in one-
third of MCL tumors.63 More recent data have indicated that 
PTEN might not be lost in MCL cells, but rather may persist 
in an inactivated form secondary to constitutive phosphory-
lation.64 In contrast to earlier studies that predicted that Akt 
upregulation would be more common in the rare blastoid 
variant of MCL, new data suggest that Akt activation might 
be just as common in normal variants of MCL.64
Given these findings, the treatment of MCL cells with 
rapamycin seemed to be the next logical step for researchers. 
Reports from earlier data demonstrated the effects of rapamy-
cin in significantly reducing cyclin D1 levels in some in vitro 
cell cultures, presumably by delaying its accumulation.65 
One study demonstrated a decrease in cyclin D1 mRNA 
translation secondary to the loss of eIF4E in rapamycin-
treated cells, which could explain the decrease in cyclin 
D1 accumulation.40 Interestingly, cyclin D1 levels in MCL 
cells treated with rapamycin were not significantly altered, 
suggesting that cyclin D1 might not be the primary target of 
mTOR inhibition in this disease, but rather a downstream 
effect of mTOR inhibition.66 The direct effect of rapamycin 
on cyclin D1 warrants further study.
What is known about rapamycin is its ability to bind 
intracellular FKBP12 and form a complex that inhibits the 
activity of mTORC1. Thus, mTORC1 is also known as the 
rapamycin-sensitive complex. Since FKBP12–rapamycin is 
not known to exhibit similar action on mTORC2, the latter 
is known as the rapamycin-insensitive complex. Scientific 
interest in mTORC2 inhibition arises partly from its abil-
ity to activate Akt signaling and overcome the negative 
feedback mechanism that normally takes place secondary 
to PI3K activation.
Clinical data on the use of temsirolimus 
in MCL
The National Cancer Institute (NCI) identified rapamycin as 
a potential anticancer therapy in 1981 and began studying 
its effects on a variety of human cancers.67 The develop-
ment of rapamycin as an anticancer therapy, however, was 
limited by its low oral bioavailability (about 14%) and low 
solubility in aqueous solutions.68 This led to the development 
of temsirolimus (rapamycin-42-[2,2-bis-(hydroxymethyl)]-
propionate), a naturally occurring water-soluble ester analog 
of rapamycin with improved stability and bioavailability 
when administered intravenously (IV).69 The main in vivo 
metabolite of temsirolimus is rapamycin (sirolimus), and 
both molecules exhibit similar potency with regard to mTOR 
inhibition. Similar to rapamycin, temsirolimus binds with 
high affinity to FKBP12, decreasing phosphorylation of 
S6K1 and 4E-BP1, inhibiting mRNA synthesis, and resulting 
in an approximately 15% decrease in protein synthesis.69 
Preclinical studies with temsirolimus demonstrated its ability 
to delay tumor progression in a variety of human cancer 
models.70–73
A dose-escalation study with temsirolimus was under-
taken in patients with advanced cancers on the basis of 
activity of temsirolimus in animal models.74 Temsirolimus 
was administered once weekly at a starting dose of 7.5 mg/m2, 
and each cycle consisted of four consecutive weekly doses. 
Rates of immunosuppression were low throughout the study, 
even in patients receiving the highest dose of 220 mg/m2. The 
most frequent adverse effects seen were stomatitis, rash, and 
hypercholesterolemia. The main dose-limiting toxicity of 
temsirolimus in this study was reversible thrombocytopenia. 
To find the most appropriate dose for patients, a simulation 
test was performed to compare the pharmacokinetics between 
body surface area-based dosing vs fixed/flat dosing. The 
study showed no difference in the area under the curve and 
low interpatient variability between the dosing schemas, 
suggesting that the use of fixed doses would be appropriate 
for further analyses.74
Of the groups of patients with cancer exposed to temsi-
rolimus in early clinical trials, those with renal cell cancer 
(RCC) appeared to accrue the largest potential benefit from 
this therapy. A large Phase III randomized trial demonstrated 
an increase in OS with temsirolimus over interferon alfa, 
which had been the standard of care for RCC at the time.75 
In 2008, temsirolimus was FDA approved for the treatment 
of patients with advanced RCC with poor prognostic features. 
The approved dose was based on Phase II trials showing the 
efficacy and safety of weekly infusion with a flat dose of 
25 mg delivered IV .76 Since the terminal half-life of rapamy-
cin is about three times that of temsirolimus (54.6 hours 
vs 17.3 hours), the weekly dosing schedule was thought to 
provide sustained clinical activity between doses.77
On the basis of prior research on rapamycin activity in 
MCL cells, researchers began to assess the effects of single-
agent temsirolimus in patients with relapsed MCL. One Phase 
II trial of temsirolimus for MCL included patients who had 
relapsed or were refractory to one or more lines of prior 
therapy. For inclusion in this study, all patients had to have OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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cyclin D1-positive tumors as determined by IHC analysis 
or t(11;14)(q13;q32) demonstrated by FISH assay as well 
as measurable disease (defined as a lymph node or tumor 
mass $2 cm or lymphocytosis with an absolute neutrophil 
count $5,000). The median age of this study population was 
70 years, with most patients having stage IV disease and 
most having relapsed after an average of four prior lines of 
therapy. Patients were treated with a flat dose of 250 mg IV 
once weekly, with each cycle consisting of four doses. The 
ORR was 38%, with one patient’s disease achieving complete 
response (CR) and twelve patients’ diseases achieving partial 
response [PR; 13 of 34 patients; 90% confidence interval (CI): 
24%–54%]. The median time to response was 1 month, with 
eight responses occurring after just one cycle. The median OS 
was 12 months (95% CI: 6.7 months to not yet reached) at 
study completion. Among responders, the median duration of 
response was 6.9 months (95% CI: 5.2–12.4 months). Three 
patients went off study because of intolerable side effects or 
a perceived decrease in quality of life while on treatment. 
The most common adverse effects seen in this study were 
thrombocytopenia, hyperglycemia, anemia, neutropenia, 
hypertriglyceridemia, mucositis, fatigue, infection, rash, 
nausea, weight loss, aspartate aminotransferase elevations, 
dysgeusia, hypercholesterolemia, and sensory neuropathy. 
Most patients (88%) required dose reductions secondary to 
adverse effects, and the study was amended to incorporate 
dose reductions down to 50 mg IV weekly.
Given the high rate of myelosuppression in the previous 
study, another Phase II trial was initiated using the FDA-
approved dose of 25 mg IV weekly for RCC. The authors 
analyzed whether adverse effects could be reduced while 
maintaining efficacy for MCL. As in the previous study, 
only patients with relapsed or refractory MCL with cyclin 
D1 positivity and measurable disease were included in this 
study. Baseline patient characteristics were also similar to 
those of the previous study, with a median patient age of 69, 
stage IV disease in 86% of patients, and an average of four 
prior lines of therapy. The ORR was 41% (11 of 27 patients; 
90% CI: 22%–61%) with 1 CR and 10 PRs. Analogous to 
the previous study, median time to response was 1 month. 
The median OS was higher in this study at 14 months (95% 
CI: 10–27 months), and the median duration of response 
for the 11 responders was 6 months (range, 1–26 months). 
Overall, 70% of patients needed dose reductions or treatment 
delays secondary to adverse effects, which was less than that 
seen in the previous study. Again, thrombocytopenia was 
the most common side effect and the most common cause 
of dose reductions, with 82% of patients experiencing a 
decrease in platelet counts at the starting dose. Most cases 
of thrombocytopenia resolved quickly when treatment was 
delayed by an average of 1 week. The authors concluded that 
the 25 mg/week dose of temsirolimus had similar efficacy to 
and better tolerability than higher doses.
To verify a true dose–response relationship, a multicenter 
Phase III trial compared two doses of temsirolimus, 25 mg 
and 75 mg IV weekly, against other single-agent therapies 
  chosen by the investigator.78 Those chosen by the   investigator 
included agents that had been studied for relapsed MCL, 
such as thalidomide, lenalidomide, and fludarabine, among 
others. Patients treated with temsirolimus at the 75 mg 
dose had a significantly longer PFS (4.8 vs 1.9 months, 
P = 0.0009; 97.5% CI: 0.25–0.78) and higher ORR (22% 
vs 2%, P = 0.0019) than patients who received one of the 
investigator’s choice therapies. Patients on the 25-mg dose 
showed a trend toward increased PFS and ORR, but this was 
not statistically significant at the time of study completion. 
Median OS did not differ significantly between groups. The 
only adverse effect that occurred with a significantly higher 
incidence in the temsirolimus arms than in the   investigator’s 
choice therapy arms was thrombocytopenia. Grade 3 or 4 
adverse effects occurred more often with the 75-mg dose than 
with the 25-mg dose (89% vs 80%). The authors concluded 
that there was a dose–response relationship with temsirolimus 
in MCL based on the differences seen in PFS and overall 
responses in this study and recommended that 75 mg should 
be the accepted dose for further studies in MCL. In 2009, 
the European Commission approved temsirolimus for the 
treatment of adult patients with relapsed or refractory MCL, 
based on this trial.
Pharmacokinetics of temsirolimus
Both temsirolimus and its primary metabolite rapamycin are 
metabolized hepatically and excreted in the feces.77 When 
temsirolimus is dosed weekly, its concentration decreases to 
subnanomolar levels within 3–4 days after administration. 
However, rapamycin remains at therapeutic levels for an 
extended period of time and likely exerts the primary antitu-
mor effect of temsirolimus.74 An in vitro study of the metabo-
lism of temsirolimus demonstrated that exposure to human 
liver microsomes resulted in the formation of 15   different 
metabolites; the major enzyme involved in biotransfor-
mation of temsirolimus was found to be CYP3A4.79 The 
  clinical significance of this finding is that practitioners must 
be alert to the potential for drug–drug interactions with OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  temsirolimus. A study of the effects of administering a potent 
CYP3A4 inhibitor (in this case, ketoconazole) on systemic 
exposure to temsirolimus demonstrated the need for a 50% 
reduction in the dose of temsirolimus when given together.80 
A Phase I trial is currently underway to assess the need for 
temsirolimus dose adjustments in patients with compromised 
hepatic function.
The clinical studies that led to the approval of temsiroli-
mus for RCC did not include patients with decreased renal 
function. Since less than 5% of the drug is cleared renally, 
the manufacturer suggests that no dose adjustments need 
be made for renal impairment.77 A small study in patients 
with RCC compared the pharmacokinetic parameters of 
temsirolimus and rapamycin in patients with normal kidney 
function with those receiving hemodialysis and did not find 
a statistically significant difference.81 The authors concluded 
that temsirolimus clearance was not affected by dialysis given 
its large molecular weight (1,030 Da) and large volume of 
distribution.
Select adverse effects of temsirolimus in MCL
Targeted therapies often exhibit a diverse array of side effects 
not seen with conventional cytotoxic chemotherapy agents, 
some of which can be linked to their mechanisms of action. 
For example, hyperlipidemia is commonly seen in patients 
treated with temsirolimus, the mechanism behind which may 
be secondary to the inhibition of Akt in adipose tissue by 
rapamycin.82 In normal adipose cells, Akt function is depen-
dent on insulin stimulation and (once activated) can suppress 
lipolysis. In rapamycin-treated cells, Akt inhibition can result 
in increased lipolysis and an accumulation of free fatty acids, 
resulting in the hepatic generation of triglycerides.83 Pulmonary 
toxicity also has been observed in clinical trials with temsi-
rolimus in patients with MCL.31,32,78 Symptoms ranged from 
increased cough or dyspnea to more severe adverse effects, 
such as grade 3 pleural effusions and hypoxia. In rare cases, a 
severe adverse reaction known as interstitial pneumonitis has 
been seen. The mechanism of this toxicity is not well under-
stood, but may be due to an increase in NF-kappaB activation 
secondary to mTOR inhibition. NF-kappaB is a ubiquitous and 
inducible heterodimer that mediates the induction of proinflam-
matory cytokines and thus may explain the pathogenesis of 
pulmonary toxicity from temsirolimus.84 Dermatologic side 
effects from temsirolimus were most commonly manifested 
as a maculopapular rash on the face/neck and an acne-like rash 
on the face and upper chest. A possible explanation for this 
toxicity could be that mTOR effects epidermal growth factor 
receptor (EGFR) in normal skin.72
Discussion
Treatment options for MCL have expanded since its clas-
sification as a separate and unique disease within NHL in 
the early 1990s. While therapeutic strategies for frontline 
therapy are still evolving, the lack of a reliable standard 
of care makes treating this disease rather challenging. 
In general, as the number of treatments to which a patient 
has been exposed increases, the likelihood of a response to 
additional agents decreases.78 Therefore, it is imperative to 
find efficacious frontline regimens that decrease a patient’s 
likelihood of relapse.
The application of R-CHOP as a standard-of-care treat-
ment in MCL has been disputed given the failure of early 
studies to show an increase in OS. It was hoped that more 
dose-intense strategies, such as R-hyperCVAD/MA, would 
show a clear advantage over R-CHOP, but newer data 
question this. Given the conflicting evidence, a   standard 
chemotherapy option for frontline treatment for MCL 
does not exist yet. To establish a standard of care, further 
research in this area is needed with prospective multicenter 
comparative trials. Data on early treatment with autologous 
hematopoietic stem cell transplantation are promising and 
seem to suggest an OS advantage for patients who respond 
well to frontline chemotherapy regimens (such as R-CHOP 
and R-hyperCVAD/MA).
In view of the conflicting data on frontline strategies, the 
controversy over which therapeutic strategy is most effica-
cious for newly diagnosed patients will persist. Clinicians 
are continuing to search for a better understanding of why 
some patients respond to a given type of treatment when 
others do not. The use of MIPI scores to predict outcomes 
is still in the early stages given its relatively new inception, 
and its utility may not be validated for some time. In the 
meantime, the search for effective second-line treatments 
that can prolong survival is becoming increasingly important. 
With researchers’ growing understanding of the molecular 
pathways involved in the pathogenesis of MCL, the options 
for second-line treatment are expanding.
An ideal second-line agent would be able to prolong DFS, 
lacks a maximum cumulative dosage limit so that patients 
could continue on treatment as long as they respond, and has 
manageable toxicities. Thus far, the efficacy of second-line 
agents seems to be similar whether single agents or combina-
tion regimens are used, offering average ORRs of 60%–70%. 
Temsirolimus has become a promising therapeutic option 
in this setting and seems to offer several advantages. The 
weekly intravenous doses can be given on an outpatient basis 
as a short infusion, increasing the ease of administration and OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
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compliance of patients. It does not require dose adjustments 
for renal dysfunction, which is advantageous in a largely 
elderly population who may have decreased renal function 
secondary to comorbidities or prior treatments. Lastly, its 
unique side-effect profile does not overlap greatly with those 
of the prior therapies to which this population is likely to 
have been exposed.
The use of temsirolimus in the frontline setting also 
  warrants investigation. The combination of chemotherapy 
and rapamycin showed potent activity against Akt-expressing 
lymphoma cells in murine models and might help in   treating 
cells otherwise resistant to chemotherapy agents such as 
cyclophosphamide and doxorubicin.85 Thrombocytopenia 
is one of the dose-limiting toxicities for temsirolimus in the 
MCL population, which is understandable in a population of 
patients who may have had multiple lines of prior therapy 
(around four, as noted previously), prior hematopoietic stem 
cell transplantation, or bone marrow involvement of their 
lymphoma. The rates of such toxicity might be less frequent 
in the frontline setting, where patients have healthier and 
less-suppressed bone marrow.
In addition to temsirolimus, two other rapamycin analogs 
are currently in clinical trials: everolimus (RAD001) and 
deferolimus (AP23573). Everolimus is FDA approved for 
patients with RCC who have progressive disease following 
first-line therapy.86 Its mechanism of action is parallel to that 
of temsirolimus, and it is available in an oral formulation. 
In vitro data demonstrate that everolimus inhibits mTOR 
activity in MCL cell lines, causes a dose-dependant decrease 
in phosphorylated 4E-BP1, and results in the enhancement 
of G1 cell-cycle arrest.87 In addition, everolimus exhibited 
synergistic activity in vitro when combined with other agents 
used in MCL such as doxorubicin, vincristine, rituximab, and 
bortezomib.87 Deferolimus is currently undergoing Phase 
II trials in patients with relapsed or refractory hematologic 
malignancies.88 Currently, the optimal use of temsirolimus 
in MCL is still being elucidated. Researchers are trying to 
understand mechanisms of resistance to temsirolimus to 
overcome them and optimize treatment. One mechanism of 
resistance may be the unexpected upregulation of mTORC2 
corresponding with mTORC1 inhibition by temsirolimus. 
However, scientists have hypothesized that prolonged 
exposure to rapamycin may help inhibit both mTORC2 and 
mTORC1, which warrants the investigation of alternate 
dosing strategies for temsirolimus to overcome this mecha-
nism of resistance.47 Unlike the binding of rapamycin to a 
preformed mTORC1, the inhibition of mTORC2 may hap-
pen prior to its formation. Since both complexes need free 
mTOR to form their respective complexes, the inhibition of 
free mTOR may be the causal factor in mTORC2 inactiva-
tion.83 Resistance to temsirolimus may also occur through 
the upregulation of eIF4E independent of mTOR activation. 
The increase in eIF4E can restore Akt action on the cell 
membrane and circumvent the effects of mTOR inhibition by 
temsirolimus.85 Therefore, agents directly targeting upstream 
factors such as Akt deserve investigation and might help 
overcome this resistance pathway when used in combination 
with temsirolimus.
A new generation of drugs known as small-molecule 
mTOR kinase inhibitors is currently in Phase I clinical trials.89 
Unlike rapamycin analogs that require binding to FKBP12, 
these agents exert their effects by directly inhibiting mTOR 
kinase and blocking the formation of both mTORC1 and 
mTORC2. Among this class of agents are the dual inhibitors 
of mTOR kinase and PI3K. By targeting various components 
of the PI3K/Akt/mTOR pathway, these agents may be able to 
overcome resistance to rapamycin and increase cytotoxicity.
Conclusion
The treatment of MCL has evolved greatly in the last decade. 
The application of targeted therapies in the second-line 
setting has expanded treatment options for patients with 
relapsed or refractory disease. The use of mTOR inhibitors 
is especially promising in view of the data on deregulated 
PI3K/Akt/mTOR pathways in MCL. Several new agents in 
this class are in the pipeline, and new dosing strategies for 
existing agents are still being explored. Thus far, temsiroli-
mus has shown clinical efficacy in this patient population as 
a single-agent treatment with a favorable side-effect profile. 
Further research is needed to study this drug in combina-
tion with other targeted agents and chemotherapy. Finding 
efficacious treatments for relapsed or refractory disease is 
fundamental to increasing survival rates and durations for 
patients with this rare and aggressive disease.
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